Abstract:Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Ministry of Science, Innovation and Universities, Spain by Consejería de Educación, Cultura y Deportes. Junta de Comunidades de Castilla-La Mancha. Background Phospholamban regulates SERCA2a pump activity by reducing its calcium affinity in the heart. Under β-adrenergic stimulation, protein kinase A (PKA) phosphorylates phospholamban attenuating its inhibitory effect on SERCA2a. The phospholamban mutation Arg 9 to Cys (R9C) was firstly identified in an American family with ventricular dilatation and premature death, and subsequently in a cohort of dilated cardiomyopathy patients in South Africa. Emerging evidence suggests that phospholamban R9C is a loss-of-function mutation with autosomal dominant inheritance. In vitro studies revealed that it enhances pentamer assembly by disulfide bridge formation, reducing the availability of phospholamban monomers to regulate SERCA2a. Purpose The present study aimed to investigate defects in Ca2+ handling and cardiac function of phospholamban R9C mutation in an in vivo zebrafish model. Methods We generated transgenic zebrafish lines overexpressing phospholamban wild-type (TgPLNwt) and phospholamban R9C (TgPLNR9C) in the heart of zebrafish. To measure calcium kinetics in 3 day-old larvae, TgPLNwt and TgPLNR9C fish were outcrossed with transgenic zebrafish lines expressing the fluorescent calcium biosensor mCyRFP1-GCaMP6f (TgRFP-GcaMP6f) and the bioluminescence calcium biosensor GFP-Aequorin (TgGA) in the heart. Results Overexpression of phospholamban wild-type and R9C did not alter the heart rate compared to sibling larvae, and no differences were observed in the upstroke and recovery time of the calcium transients. However, atrial and ventricular calcium transient amplitude were higher in TgPLNR9C larvae with respect to TgPLNwt larvae. Contractile force of the heart, assessed as the fractional shortening, increased in TgPLNR9C larvae compared to siblings and TgPLNwt. Furthermore, stroke volume and cardiac output were also higher in TgPLNR9C larvae. Bioluminescence experiments were performed to estimate the average calcium levels in the heart. We found that TgPLNR9C larvae showed higher calcium levels than sibling and TgPLNwt larvae. To evaluate the responsiveness to β-adrenergic stimulation, larvae were treated with the β-agonist isoproterenol. Calcium transient amplitude and contractile force increased in sibling and TgPLNwt larvae after treatment. However, this response was absent in TgPLNR9C larvae, suggesting that they were hyper-stimulated in basal conditions, displaying amplitude and contractile force similar to sibling and TgPLNwt larvae treated with isoproterenol. Conclusion TgPLNR9C larvae exhibited aberrant calcium handling in the heart with higher calcium levels and contractility, consistent with a lack of inhibition of SERCA2a. Consequently, TgPLNR9C larvae did not respond to β-adrenergic stimulation. These results were consistent with previous in vitro studies carried out in cardiomyocites infected with phospholamban R9C and highlighted the pathological defects of phospholamban R9C at early stages of the disease.

ZBTB20 Regulates SERCA2a Activity and Myocardial Contractility Through Phospholamban

[Effects of Tumor Necrosis Factor Alpha on Expression of Phospholamban and Intracellular Calcium in Cardiomyocytes].

Abstract 9763: Cardiac Beta-arrestin2 Promotes Contractility by Enhancing SERCA2a SUMOylation and Activity

Attenuation of the Upregulation of NF‑κB and AP‑1 DNA‑binding Activities Induced by Tunicamycin or Hypoxia/reoxygenation in Neonatal Rat Cardiomyocytes by SERCA2a Overexpression.

Hypoxia-responsive zinc finger E-box-binding homeobox 2 (ZEB2) regulates a network of calcium-handling genes in the injured heart

Cardioprotective Effects Of Serca2a Overexpression Against Ischemia-Reperfusion-Induced Injuries In Rats.

SERCA2 phosphorylation at the heart of the disease

Intracellular β1-Adrenergic Receptors and Organic Cation Transporter 3 Mediate Phospholamban Phosphorylation to Enhance Cardiac Contractility

Phenotyping calcium and contraction in a zebrafish model of phospholamban R9C mutation

Intracellular Β 1 -Adrenergic Receptors and Organic Cation Transporter 3 Mediate Phospholamban Phosphorylation to Enhance Cardiac Contractility

Remodelling of cAMP dynamics within the SERCA2a microdomain in heart failure with preserved ejection fraction caused by obesity and type 2 diabetes

Phospholamban Knockout Breaks Arrhythmogenic Ca2+ Waves and Suppresses Catecholaminergic Polymorphic Ventricular Tachycardia in Mice

Abstract MP140: Epigenetic Silencing of SERCA2a by Long Noncoding RNA Lnc-SYNPO Contributes to Impaired Ca 2+ Homeostasis and Contractility in the Failing Heart

The atypical 'b' splice variant of phospholipase Cβ1 promotes cardiac contractile dysfunction

Rescue of Cardiomyocyte Dysfunction by Phospholamban Ablation Does Not Prevent Ventricular Failure in Genetic Hypertrophy.

Phosphoinositide 3-Kinase C2alpha controls cardiac contractility through regulation of beta2-adrenergic receptor recycling

Protein docking and steered molecular dynamics suggest alternative phospholamban-binding sites on the SERCA calcium transporter

HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization

Overexpression of PEP-19 suppresses angiotensin II-induced cardiomyocyte hypertrophy.

Sirtuin 1 Represses PKC‐ζ Activity Through Regulating Interplay of Acetylation and Phosphorylation in Cardiac Hypertrophy

Critical Role of Znhit1 for Postnatal Heart Function and Vacuolar Cardiomyopathy